Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02310698 · ClinicalTrials.gov registry record
Comparison of Whole Breast Screening Ultrasound and Contrast Enhanced Mammography for Supplemental Breast Cancer Screening
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 487
- Enrollment target
NCT02310698: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02310698 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 487 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02310698 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 487 participants
- Enrollment target
Study Summary
Breast tumors are often detected on mammography but may be harder to see in women with dense breasts. This is why screening breast ultrasound is sometimes used as another test in women with dense breasts. Ultrasound has been shown to detect additional cancers that are not seen on regular mammography. Contrast Enhanced Digital Mammography (CEDM) is a FDA approved form of mammography. It is essentially a routine digital mammogram performed after iodine dye (the same that is used with CT scans) is injected into a vein in the arm. Like screening ultrasound, CEDM has been shown to detect breast cancers that are not seen on a regular mammogram. The purpose of this study is to compare whether CEDM or screening breast ultrasound is better at detecting cancer. Both will be done in this study and compared to one another.
Primary Outcome
With respect to imaging, a positive test is defined by a recommendation for biopsy (BIRADS 4 or 5). Negative imaging tests are those with BIRADS 1-3. The number of recommendations for short term follow up (BI-RADS 3) will also be recorded.
Interventions
- DEVICE contrast enhanced digital mammography (CEDM)
- DEVICE whole breast screening ultrasound (WBUS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 487 participants |
| Start Date | 2014-12-02 |
| Est. Completion | 2025-03-26 |
What the finished NCT02310698 record still lists
NCT02310698 is an observational study that tracks outcomes without assigning an intervention. The registered 487 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which contrast enhanced digital mammography (CEDM) is the first listed.
NCT02310698 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02310698 about?
NCT02310698 is a clinical study titled "Comparison of Whole Breast Screening Ultrasound and Contrast Enhanced Mammography for Supplemental Breast Cancer Screening". Breast tumors are often detected on mammography but may be harder to see in women with dense breasts. This is why screening breast ultrasound is sometimes used as another test in women with dense breasts. Ultrasound has been shown to detect additional cancers that are not seen on regular mammography...
What is the current status of trial NCT02310698?
This trial is currently completed. The enrollment target is 487 participants. The study started on 2014-12-02. Estimated completion is 2025-03-26.
What interventions are being tested in trial NCT02310698?
The interventions under investigation include: contrast enhanced digital mammography (CEDM) (DEVICE), whole breast screening ultrasound (WBUS) (DEVICE).
Who is sponsoring clinical trial NCT02310698?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06948435 · 487 participants · Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
- NCT06952530 · 487 participants · Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
- NCT05154669 · 488 participants · Phase 3
Integrating Financial Coaching and Smoking Cessation Coaching
- NCT06532877 · 488 participants · NA
Telephone Support in Advanced Gastrointestinal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI